Abrégé

Methods and kits for mitigating lung injury in a subject treated with a targeted radiation therapy or otherwise exposed to radiation are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced lung injury.

Classes IPC  ?

• A61K 38/19 - CytokinesLymphokinesInterférons
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• A61N 5/00 - Thérapie par radiations
• A61P 35/00 - Agents anticancéreux

Abrégé

Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RARα) in subjects in need thereof.

Classes IPC  ?

• C07C 279/22 - Y étant un atome d'hydrogène ou de carbone, p. ex. benzoylguanidines
• C07D 265/36 - Oxazines-1, 4Oxazines-1, 4 hydrogénées condensés avec des carbocycles condensés avec un cycle à six chaînons
• C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques

Abrégé

Provided herein are methods of determining a subject's level of exposure to radiation and methods of determining a subject's risk of subsequent development of radiation disease or risk of poor prognosis from radiation exposure that include determining a level of one or more miRNAs selected from the group consisting of mouse and human homologues of mouse miR-130a-3p, miR-150-5p, miR-17-3p, miR-187-3p, miR-194-5p, miR-27a-3p, miR-30a-3p, miR-30c-5p, miR-142-5p, miR-342-3p, miR-34b-3p, miR-126- 3p, miR-320-3p, miR-136-5p, miR-33-5p, miR-142a-3p, miR-706, miR-375-3p, miR-29a- 5p, miR-193a-3p, miR-99b-5p, miR-151-3p, miR-let-7d-3p, miR-486-5p, miR-423-5p, miR-30b-5p, miR-191-5p, miR-497a-5p, miR-32-5p, miR-214-5p, miR-326-3p, miR-1195, miR-122-5p, miR-1839-3p, miR-500-3p, miR-30e-3p, miR-322-3p, miR-709, miR-486-3p, miR-133a-3p, miR-676-3p, miR-744-5p, miR-29a-3p, miR-1839-5p, miR-30a-5p, miR- 199b-5p, miR-125a-5p, miR-133b-3p, miR-24-3p, miR-21a-5p, miR-503-5p, miR-328-3p, miR-let-7g-5p, miR-362-3p, miR-199a-5p, miR-15a-3p, miR-139-5p, miR-149-5p, miR- 29b-3p, miR-la-3p, miR-23b-3p, miR-215-5p, miR-204-5p, miR-200b-5p, miR-25-3p, miR-338-3p, and miR-196b-5p, in a sample including a biological fluid from the subject.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
• A01H 1/06 - Procédés de mutation, p. ex. traitements par produits chimiques ou irradiations
• A61B 6/08 - Moyens auxiliaires pour diriger le faisceau de radiations sur un point particulier, p. ex. en utilisant des faisceaux lumineux
• A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
• A61M 36/04 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention provides mycobacterial plasmids expressing antigens and immunogenic compositions comprising these plasmids, methods for quality control of such compositions, and their use in immunization methods.

Classes IPC  ?

• A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/20 - BactériesLeurs milieux de culture
• A61P 37/04 - Immunostimulants
• C12N 15/09 - Technologie d'ADN recombinant
• C12R 1/32 - Mycobacterium

Abrégé

Humanized Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infections and diseases are also provided. The presently claimed invention was made by or on behalf of the below listed parties to a joint research agreement. The joint research agreement was in effect on or before the date the claimed invention was made and the claimed invention was made as a result of activities undertaken within the scope of the joint research agreement.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using inhibition of p21 protein (Cdc42/Rac)-activated kinase (PAK1).

Classes IPC  ?

• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

Methods are provided for determining if a subject is likely to develop an age-related disease based on miRNA signatures. Related methods of treatment are also provided.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides

Abrégé

Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

The present invention provides biomarkers, methods and kits for diagnosing active tuberculosis in a subject, methods and kits for monitoring the effectiveness of treatment for active TB, as well as methods for identifying a compound that can treat TB reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat active TB.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated mutant PD-1 polypeptide fused to an immunoglobulin domain polypeptide are provided. Further provided are methods of using a composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/00 - Préparations médicinales contenant des peptides
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide

Abrégé

The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

Classes IPC  ?

• C07H 15/18 - Radicaux acycliques substitués par des carbocycles
• A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 33/00 - Agents antiparasitaires
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Methods and systems for identifying inhibitors of Equilibrative Nucleoside Transporters are provided. Methods and systems for identifying inhibitors of Concentrative Nucleoside Transporters are also provided.

Classes IPC  ?

• C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides

Abrégé

Methods are provided for identifying an agent as a selective inhibitor of a Bcl-2-associated x-protein (BAX).

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 2/00 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

Methods and systems for high-throughput Identification of receptor: ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

Classes IPC  ?

• C40B 30/06 - Procédés de criblage des bibliothèques en mesurant les effets sur des cellules, des tissus ou des organismes vivants

Abrégé

Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction.

Classes IPC  ?

• C07D 211/56 - Atomes d'azote
• C07D 211/92 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec un hétéro-atome lié directement à l'atome d'azote du cycle

Abrégé

Methods and products are provided for producing an artery-specific endothelial cell. Also provided are methods for treating a tumor in a subject.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance

Abrégé

Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Provided are compositions comprising a plurality of isolated mycobacterium membrane vesicles, and methods of use thereof, and methods of improving the efficacy of immunizations. Throughout this application various publications are referred to by number in parentheses. Full citations for the references may be found at the end of the specification. The disclosures of each of these publications, and also the disclosures of all patents, patent application publications and books recited herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

Classes IPC  ?

• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis

Abrégé

The present invention relates to methods and kits for detecting active tuberculosis infection in a subject using serological techniques and a first agent capable of binding an IgG, IgA and/or IgM directed to the first protein present in or on a Mycobacterium tuberculosis membrane vesicle or a Bacillus Calmette-Guerin (BCG) membrane vesicle. Also provided are methods of treating a subject with an active tuberculosis disease.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Abrégé

Provided are method of synthesizing (R)-5-diphosphomevalonate (DPM), isopentenyl 5-pyrophosphase (IPP), dimethylallyl 5 -pyrophosphate (DMAPP) and isoprenoid using a one-pot synthesis.

Classes IPC  ?

• C12P 5/02 - Préparation des hydrocarbures acycliques
• C12P 5/00 - Préparation des hydrocarbures
• C12P 7/04 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle acycliques

Abrégé

Methods and devices are disclosed for treating or preventing infections in a subject due to Pseudomonas aeruginosa using coformycin analogs and inhibitors of Pseudomonas aeruginosa 5'-methylthioadenosine deaminase (MTADA).

Classes IPC  ?

• A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
• C07H 19/00 - Composés contenant un hétérocycle partageant un hétéro-atome du cycle avec un radical saccharideNucléosidesMononucléotidesLeurs anhydro-dérivés

Abrégé

Provided are composition and methods for treating radiation-induced cell damage, and in particular aspects to methods for protecting, mitigating or otherwise treating radiation-induced induced depletion of tissue stem cells and injury to the supportive stem cell niche, and in even more particular aspects to methods for protecting, mitigating or otherwise treating radiation-induced gastrointestinal syndrome (RIGS), comprising sequential administration of a Wnt pathway activator/agonist (e.g., Rspo1 or a small molecule inducer thereof) that amplifies the surviving intestinal stem cell (ISC) pool post-radiation exposure, followed by a selective antagonist of the β-Catenin-CBP interaction (e.g., ICG-001 or other exemplary compounds disclosed herein) that accelerates differentiation of the stimulated (e.g., Rspo1-stimulated) ISC in crypt-villi axis, promoting villous regeneration and intestinal restitution, thereby mitigating RIGS. Adjunctive and combination therapy embodiments are encompassed.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5'-methylthioadenosine nucleosidase) to the subject.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles

Abrégé

Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt.

Classes IPC  ?

• A01N 37/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe —CO—N, p. ex. amides ou imides d'acide carboxyliqueLeurs thio-analogues
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet

Abrégé

A method of obtaining a population of PDGFRα+ CD51+ CD146high stem cells is provided. Compositions comprising PDGFRα+ CD51+ CD146hlgh stem cells, and methods of use of a population of PDGFRα+ CD51+ CD146high stem cells, are also provided.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet

Abrégé

A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen- presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.

Classes IPC  ?

• A61K 39/385 - Haptènes ou antigènes, liés à des supports
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

Methods are provided for producing differentiated cells from stem cells, including producing hepatocytes. Compositions thereof are also provided, as are methods of treating a liver disorder.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet

Abrégé

Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens
• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger

Abrégé

Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.

Classes IPC  ?

• A61K 31/04 - Composés nitrés

Abrégé

Provided are methods of using humanin and humanin analogs to increase insulin secretion in a subject.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

Aptamers targeted to a human transferrin receptor which do not compete with transferrin for binding are provided. Compositions and methods for aptamer-targeted liposomal drug delivery are also provided.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• C40B 50/06 - Procédés biochimiques, p. ex. utilisant des enzymes ou des micro-organismes viables entiers

Abrégé

Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.

Classes IPC  ?

• A61K 38/38 - Albumines
• A61K 38/42 - HémoglobinesMyoglobines
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• C07K 14/805 - HémoglobinesMyoglobines
• C07K 14/76 - Albumines
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire

Abrégé

Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c).

Classes IPC  ?

• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides

Abrégé

The present invention provides methods for determining a putative agent that treats or prevents obesity and/or diabetes or increasing insulin sensitivity, the method comprising contacting cells with the putative agent and measuring thioredoxin-interacting protein (TXNIP) or thioredoxin expression or activity in the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of preventing or treating obesity and/or diabetes or of increasing insulin sensitivity or glucose sensitivity, the method comprising administration of the agent that decreases the expression of TXNIP or activity of TXNIP.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Methods and systems for obtaining inhibitors of human immunodeficiency virus- 1 (HIV-1) protease are disclosed where the methods involve designing compounds that resemble the HIV-1 protease transition state.

Classes IPC  ?

• A01N 43/36 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à cinq chaînons

Abrégé

A method of detecting a microRNA present in a lung of a subject comprising amplifying, from a sample of exhaled breath condensate from the subject, a microRNA present therein by reverse transcription-polymerase chain reaction (RT-PCR) of the microRNA to corresponding DNA. Detection of pathogenic organisms or macromolecules in the lung are also encompassed.

Classes IPC  ?

• G01N 33/497 - Analyse physique de matériau biologique de matériau biologique gazeux, p. ex. de l'haleine

Abrégé

Methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) ΙκΒ kinase β (ΙΚΚβ) activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κΒ) or (ii) Notch signaling, in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity'.

Classes IPC  ?

• C12N 5/0797 - Cellules souchesCellules progénitrices
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

Luciferase-linked methods for detecting adenosine and for screening for inhibitors of enzymes that produce adenosine are disclosed. The invention also provides methods for detecting the presence of Sadenosyl-L-homocysteine hydrolase (SAHH) comprising: (a) hydrolysis of S-adenosyl-Lhomocysteine (SAH) catalyzed by S-adenosyl-L-homocysteine hydrolase (SAHH) to adenosine and L-homocysteine; (b) converting adenosine to adenosine monophosphate (AMP) by adenosine kinase in the presence of a phosphate donor; (c) converting AMP to adenosine 5 '-triphosphate (ATP) by pyruvate phosphate dikinase (PPDK) in the presence of phosphoenolpyruvate (PEP) and inorganic pyrophosphate; and (d) reacting A TP with luciferin and Oz in the presence of luciferase to produce AMP and a luminescent signal, wherein the luminescent signal indicates the presence of S-adenosyl-L-homocysteine hydrolase (SAHH).

Classes IPC  ?

• C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une luciférase

Abrégé

Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies. An isolated antibody, or an isolated antigen-binding fragment of an antibody, is provided which antibody or antigen-binding fragment binds to staphylococcal enterotoxin B (SEB) and which antibody or antigen-binding fragment comprises a heavy chain variable CDR3 comprising the sequence RIYYGNNGGVMDY (SEQ ID N0:30); ARTAGLLAPMDY (SEQ ID N0:31); ARDTMRKCYCELKLKPPAEHPGPA (SEQ ID N0:32) or VRDL YGDYVGRY A Y (SEQ ID N0:48).

Classes IPC  ?

• C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries

Abrégé

Methods are disclosed for determining classification and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) using activation of signal transducer and activator of transcription 3 (STAT3).

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)

Abrégé

Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 5/07 - Cellules animales ou tissus animaux

Abrégé

Methods are provided for treating Parkinson's disease, protecting dopaminergic neurons from neurotoxicity and for increasing DJ-1 levels in neruons. Methods are also provided for identifying candidate treatments for Parkinson's disease.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
• A61P 25/16 - Antiparkinsoniens
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

Methods are provided for detecting mycobacteria in a sample, including clinical samples. Methods are also provided for determining susceptibility of mycobacterial strains to known or potential antibiotic agents, as are kits therefor. Recombinant mycobacteriophages are also provided comprising heterologous nucleic acids of interest.

Classes IPC  ?

• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora

Abrégé

Methods are provided for treating dementia and or impaired cognition, as well as assays useful for identifying novel anti-dementia agents. Compounds and compositions for treating dementia and or impaired cognition are also provided.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Abrégé

A combination therapy to treat a cancer or a tumor is provided. A method of delaying resistance to an anti-cancer/anti-tumor therapy is also provided.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée

Abrégé

Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow siromal cells expanded in culture, adipose-tissue derived non-adherent siromal cells, or ihe culture supernatant thereof.

Classes IPC  ?

• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet

Abrégé

Methods of treating a disease in a subject are provided comprising administering to the subject an amount of an agent which reduces, or prevents, interaction of a Gβγ with a pi 110β effective to treat the disease. Methods are also provided for identifying an inhibitor of interaction between a Gβγ and a ρ110β. Compositions are provided comprising a peptide comprising amino acid residues having the KAAEIASSDSANVSSRGGKKFLPV (SEQ ID NO:6).

Classes IPC  ?

• A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation

Abrégé

Methods are provided for determining if an agent causes somatic mutations in a genome, and kits, systems and computer-readable medium therefor.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Abrégé

Methods and compositions for treating obesity or an obesity comorbidity in a subject are provided, employing an inhibitor of synaptotagmin-4 or an amount of oxytocin or an analogue thereof. Methods and compositions for effecting weight gain in a subject are also provided employing synaptotagmin-4, or an analogue of synaptotagmin-4, or an oxytocin antagonist.

Classes IPC  ?

• A61K 38/11 - Oxytocines; Vasopressines; Peptides apparentés

Abrégé

Methods and products are provided for determining if a subject having a tumor is (i) at risk of metastasis of the tumor, or (ii) at risk of recurrence of the tumor after treatment of the tumor. Methods of treatment of cancer, tumors and metastasis are also provided. Also provided is n method of determining a subject having a tumor as (i) at risk of metastasis of the tumor, (ii) at risk of invasion of the tumor, or (iii) at risk of recurrence of the tumor after treatment of the tumor, comprising obtaining a sample of the tumor and determining the level of expression in the sample of one or more of the genes (I) in the upregulated DNA Replication and Repair section of Table 1; (2) in the upregulated Embryonic and Tissue Development section of Table I; (3) in the upregulated Cellular Movement and Development section of Table I; (4) in the upregulated Cell-to-Cell Signaling and interaction section of Table I; and/or (5) in the upregulated Cellular Assembly and Organization section of Table I.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to compounds of formula (I) that are inhibitors of hypoxanthine and/or guanine purine phosphoribosyltransferases and to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit hypoxanthine and/or guanine purine phosphoribosyltransferases. Such diseases include malaria.

Classes IPC  ?

• C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61P 33/06 - Antipaludéens

Abrégé

Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes

Abrégé

Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 14/505 - Érythropoïétine [EPO]
• A61P 35/00 - Agents anticancéreux

Abrégé

Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres

Abrégé

The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Abrégé

The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and /or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

A method of treating a tumor in a subject, or reducing or preventing metastasis of a tumor in a subject, is provided comprising administering to the subject an amount of a bacteria labelled with, or comprising, one or more radionuclides so as to treat the tumor in the subject, or so as to reduce or prevent metastasis of the tumor in the subject. Radiobacteria-containing compositions and pharmaceutical compositions are also provided.

Classes IPC  ?

• A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
• A61M 36/14 - Pansements radioactifs

Abrégé

The present invention provides resveratrol-based boron-containing analog! methods of use thereof in treatment of dyslipidemias and cancer.

Classes IPC  ?

• A01N 55/08 - Biocides, produits repoussant ou attirant les animaux nuisibles ou régulateurs de croissance des végétaux, contenant des composés organiques comportant des éléments autres que le carbone, l'hydrogène, les halogènes, l'oxygène, l'azote et le soufre contenant du bore
• A61K 31/69 - Composés du bore

Abrégé

Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux

Abrégé

Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans. The present invention provides nucleic acid constructs comprising Hindlll (AAGCTT), 2GI2 VL (SEQ ID NO:l), CL (SEQ ID NO:2), Intragenic region (SEQ ID NO:3), pel B (SEQ ID NO:4), Region X (SEQ ID 5), spe I (ACTAGT), VH (SEQ ID NO:6), CH (SEQ ID NO:7), Hinge (SEQ ID NO:8), GCN4 (SEQ ID NO:9), and Sail (GTCGAC), or a modified version thereof wherein the modification consists of one or more modification in the sequence of the 2GI2 VL region and/or on or more modification in the sequence of the VH region, and wherein the modification consists of a substitution of one codon for another codon, up to nine such substitutions, and/or insertion of up to nine additional codons.

Classes IPC  ?

• C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p. ex. bibliothèques de gènes

Abrégé

The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5'- methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.

Classes IPC  ?

• A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole

Abrégé

Methods and apparatus are disclosed for imaging molecular interactions in living cells at high resolution, low light levels and high acquisition speeds.

Classes IPC  ?

• G01N 33/559 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène dans un gel, p. ex. technique d'Ouchterlony

Abrégé

Disclosed are tris(triazolylmethyl)amine ligands, and kits and methods for labeling and/or imaging a biomolecule of interest in a subject or living system.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

Classes IPC  ?

• C12N 1/12 - Algues unicellulairesLeurs milieux de culture

Abrégé

The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA.

Classes IPC  ?

• A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles

Abrégé

The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumor-homing nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonuceotide, (ii) replacing one or more nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing the it with one or more nucleoside or nucleoside analogs; or (2) preparing a naive combinatorial aptamer, internalizing nucleic acid or tumor-homing nucleic acid prodrug library, and running iterative rounds of selection for the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of treating or preventing cancer and/or viral infection, the method comprising administration of the oligonuleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells.

Classes IPC  ?

• C40B 50/06 - Procédés biochimiques, p. ex. utilisant des enzymes ou des micro-organismes viables entiers
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide

Abrégé

The present invention provides methods for determining a putative agent that treats or prevents obesity and/or diabetes or increasing insulin sensitivity, the method comprising contacting cells with the putative agent and measuring thioredoxin-interacting protein (TXNIP) or thioredoxin expression or activity in the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of preventing or treating obesity and/or diabetes or of increasing insulin sensitivity or glucose sensitivity, the method comprising administration of the agent that decreases the expression of TXNIP or activity of TXNIP.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/28 - Insulines
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61P 7/12 - Antidiurétiques, p. ex. médicaments pour le traitement du diabète insipide

Abrégé

Disclosed are Na+/I- symporter (NIS) mutant proteins wherein glycine residue 93 is replaced with aspartic acid or glutamic acid, a method of preparing said mutant NIS protein, a transfection vector for a NIS mutant protein, and a pharmaceutical composition comprising said mutant NIS protein in a pharmaceutically acceptable carrier. The disclosure also provides a method of treating cancer or cancerous cells, comprising administering a therapeutically effective amount of a transfection vector for a NIS mutant protein or a pharmaceutical composition thereof, and administering a therapeutically effective amount of radioisotope. The disclosure further provides a method of imaging cells, comprising administering to the cells an effective amount of a transfection vector for a NIS mutant protein, administering a effective amount of imaging label, and imaging the cells.

Classes IPC  ?

• C07K 1/00 - Procédés généraux de préparation de peptides
• A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The present invention provides methods for determining if an agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity, comprising contacting Fyn and /or LKB1 with the agent and determining if the agent inhibits Fyn kinase activity or inhibits the interaction between Fyn and LKB1, wherein inhibition of Fyn kinase activity or inhibition of the interaction between Fyn and LKB1 by the agent indicates that the agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity. The present invention also provides methods for treating cancer, treating obesity, or increasing insulin sensitivity in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits Fyn kinase or that inhibits the interaction between Fyn and LKB1.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• A61K 38/45 - Transférases (2)

Abrégé

The present invention relates to methods for detecting the activity of DNA (cytosine 5)-methyltransferase, protein methyltransferase or any enzyme that forms S-adenosyl-l- homocysteine (AdoHcy) as a product, and for screening for inhibitors of DNA (cytosine 5)- methyltransferase, protein methyltransferase and any enzyme that forms S-adenosyl-l- homocysteine (AdoHcy) as a product using luciferase-linked assays that convert the S- adenosyl-l-homocysteine (AdoHcy) product to a quantifiable luminescent signal.

Classes IPC  ?

• C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions

Abrégé

The present invention provides quantitative methods for the detection of tau protein and/or tau fragments. More specifically, the present invention provides quantitative methods for diagnosing a tauopathy or ruling out a tauopathy as the cause of disease, particularly the diagnosis and ruling of Alzheimer's disease. The present invention further provides a method for diagnosing a tauopathy by computing the ratio of two detected tau proteins or tau fragments.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

The present invention provides an albumin polymer and a process of making an albumin polymer, the process comprising breaking instrinsic disulfide bridges in albumin with a reducing agent and crosslinking inter- and intra- molecular disulfide bridges so as to form the ploymer. The present invention also provides PEGylated albumin polymers and methods of making PEGylated albumin polymers, the methods comprising polymerizing albumin by crosslinking inter- and intra- molecular disulfide bridges, and PEGylating the albumin polymer. The present invention further provides a pharmaceutical composition useful as a blood plasma expander, blood substitute or for drug delivery, and methods of treating blood loss in a subject and of delivering drugs to a subject's tissue, the pharmaceutical composition comprising a therapeutically effective amount of the PEGylated albumin polymer.

Classes IPC  ?

• A61K 38/38 - Albumines
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

The present invention provides methods of treating hemophilia in a subject, the methods comprising transplanting a therapeutically effective amount of bone marrow, cord blood, cord blood or bone marrow fraction expressing Factor VIII, mononuclear cells, or mesenchymal stromal cells from a donor to the subject with hemophilia. The present invention also provides compositions for treating hemophilia.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection.

Classes IPC  ?

• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides

Abrégé

The present invention relates to methods of determining agents that inhibit Mena+ or MenaINV/+, and uses of agents that bind to and/or inhibit Mena+ or MenalNV/+ for diagnosis and treatment of metastatic tumors.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention provides a method of isolating motile cells from an animal tissue, the method comprising implanting in the animal tissue a cell trap comprising a chamber with an inlet for ingress of motile cells and a porous matrix located in the chamber comprising a chemotactic factor, for a time sufficient for the motile cells to migrate into the cell trap; removing the implanted cell trap; and retrieving the motile cells from the cell trap.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds.

Classes IPC  ?

• A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
• A61K 31/38 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle
• A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine

Abrégé

The present invention provides a device for immobilizing aquatic animals, the device comprising a receptacle for holding an aquatic animal in a volume of water, an opening in the receptacle for placement and removal of the aquatic animal, a restraint positioned inside the receptacle for restraining the aquatic animal, and a tube attached to the receptacle for supplying air or aerated water to the receptacle. The present invention further provides methods of immobilizing and imaging live aquatic animals using the device of the present invention.

Classes IPC  ?

• A01K 63/00 - Récipients pour poissons vivants, p. ex. aquariumsTerrariums

Abrégé

The present invention provides methods and kits for determining which microRNAs bind to a target mRNA where the methods comprise the steps of (a) creating a bait sequence from the target mRNA, where the bait sequence comprises a label that binds to a binding agent; (b) adding a mixture of microRNAs to the bait sequence; (c) separating the microRNAs that bind to the bait sequence from those microRNAs that do not bind; and (d) identifying the microRNAs that bind to the bait sequence, wherein the microRNAs identified are those that bind to the target mRNA.

Classes IPC  ?

• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide

Abrégé

Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.

Classes IPC  ?

• A01N 43/66 - Triazines-1,3,5 non hydrogénées et non substituées sur les atomes d'azote du cycle
• A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine

Abrégé

The present invention provides a method for determining a putative agent that inhibits the SUMO or the SUMO-targeted ubiquitin ligase pathway comprising the steps of contacting mutant MOT1 cells with the putative agent under conditions (1) permitting mutant MOT1 cell growth in the presence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor and (2) not permitting mutant MOT1 cell growth in the absence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor, and measuring cell growth.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Abrégé

Disclosed are methods of improving motor functions of a subject by administering cognitive function training to the subject. The cognitive functions trained can include executive and/or attention functions. The improved motor functions can be, for example, one or more of improved gait, increased speed of walking, increased speed of walking while talking, and decreased incidence of falling.

Classes IPC  ?

• G09B 19/00 - Enseignement non couvert par d'autres groupes principaux de la présente sous-classe

Abrégé

Disclosed are methods for determining whether a subject may have hepatic insulin resistance, for diagnosing hepatic insulin resistance, and for assessing the prognosis of a subject with hepatic insulin resistance, comprising determining the level of expression of major facilitator superfamily domain 2 protein (Mfsd2) in a subject's liver, where overexpression of Mfsd2 is indicative of hepatic insulin resistance.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

Disclosed are methods for treating liver failure in a subject comprising transplanting hepatocytes or stem or progenitor cells in an extrahepatic site in the subject in an amount sufficient to provide liver support and/or induce liver regeneration, where the transplanted hepatocytes or stem or progenitor cells are used along with extracellular matrix-coated microcarriers.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet

Abrégé

The invention provides compositions for controlled delivery and/or containment of therapeutic and/or diagnostic agents comprising the agent or agents encapsulated by a matrix containing chitosan, polyethylene glycol (PEG) and/or polyvinyl alcohol (PVA), and tetra- methoxy-ortho-silicate (TMOS) or tetra-ethoxy-ortho-silicate (TEOS), as well as methods for preparing the compositions, and uses of the compositions for therapy and imaging.

Classes IPC  ?

• A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue

Abrégé

The present invention relates to inhibitors of mitochondria-associated, granulocyte- macrophage colony stimulating factor signaling molecule (Magmas), and related compositions and uses thereof.

Classes IPC  ?

• A01N 43/40 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons
• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés

Abrégé

The present invention is directed to methods for evaluating the efficacy of a cancer treatment for (i) inhibiting metastasis in a subject, (ii) inhibiting local cancer cell movement, and (iii) inhibiting cancer cell proliferation. The present invention is further directed to methods for monitoring cell motility in a subject. The present invention is also directed to kits for performing any of the above methods.

Classes IPC  ?

• C12N 5/07 - Cellules animales ou tissus animaux
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
• G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur

Abrégé

The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

Classes IPC  ?

• C12N 1/12 - Algues unicellulairesLeurs milieux de culture
• C12N 1/20 - BactériesLeurs milieux de culture
• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis

Abrégé

Disclosed are PEGylated hemoglobins (Hbs) modified at Valine-1 (alpha) to increase tetramer stability of hemoglobin, methods of making these modified hemoglobins, and their use as blood substitutes.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

Methods are provided for designing a transition state inhibitor of orotate phosphoribosyltransferase (OPRT) and for inhibiting OPRT.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

The present invention generally relates to oxazine derivative compounds and related compositions and methods for inducing hypoxic tumor cell death, treating cancer and locating a hypoxic tumor in a subject.

Classes IPC  ?

• A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines

Abrégé

The present invention is directed to methods for detecting the presence of ricin and compounds that catalyze the release of adenine from nucleic acids or other biological materials and for screening for inhibitors of such compounds.

Classes IPC  ?

• C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
• C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une luciférase

Abrégé

The present invention provides methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5'-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor. The present invention further provides pharmaceutical compositions comprising a sub-bacterial-growth inhibiting amount of a 5'-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor and a pharmaceutically acceptable carrier.

Classes IPC  ?

• A01N 43/36 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à cinq chaînons
• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil

Abrégé

The present invention generally relates to an apparatus for structural mapping of a macromolecule comprising an amount of persulfide effective to generate hydroxyl radicals upon contact with an aqueous solution. The present invention further relates to methods for structural mapping a macromolecule in an aqueous solution and methods for structural mapping a plurality of macromolecules in parallel, wherein each macromolecule is in a separate aqueous solution.

Classes IPC  ?

• G06G 7/48 - Calculateurs analogiques pour des procédés, des systèmes ou des dispositifs spécifiques, p. ex. simulateurs
• G06G 7/58 - Calculateurs analogiques pour des procédés, des systèmes ou des dispositifs spécifiques, p. ex. simulateurs pour des processus chimiques

Abrégé

Methods are disclosed for using agents and treatments that cause the release of melanin from melanin-containing melanomas to increase the efficacy of therapy and imaging of the melanomas with radiolabeled anti-melanin antibodies and peptides.

Classes IPC  ?

• A61K 31/415 - 1,2-Diazoles

Abrégé

The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for blocking corepressor binding to a BCL6 lateral groove, methods for inhibiting BCL6 repression in a mammalian cell, and methods for treating a mammal with cancer, wherein the cancer requires BCL6 repression. The present invention is further directed to polypeptides comprising a portion of the corepressor binding site for BCL6 and related polynucleotides and vectors.

Classes IPC  ?

• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci